Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goodbye To Snail Mail: FDA Endorses E-mail For Sending Recall Notices

This article was originally published in The Pink Sheet Daily

Executive Summary

Final guidance acknowledges that e-mail is less expensive, faster and more likely to be read than traditional letters.

You may also be interested in...



FDA To Use CDRH Dispute Resolution Panel For The First Time In Years

Device center ombudsman Weinstein refers Cardima to the DRP regarding a 2002 application.

FDA Device Center Ombudsman Fields Fewer Complaints In 2005

Communications addressed to ombudsman of FDA's device center drop to three-year low of 114, according to 2005 report.

Combination Product Submissions Rose 10% In FY 2005, FDA Says

Among the 275 applications for combination products submitted were 12 NDAs, 152 INDs and two BLAs.

Topics

UsernamePublicRestriction

Register

PS064286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel